GlassScriptPhysician profile
Allison Engelbrecht
NPI 1366605347
$5,330.46
in general payments reported to CMS, 2019-2025
21 companies · $1,108 in 2025
The $1,108 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $438 · 2022: $731 · 2023: $1,651 · 2024: $1,402 · 2025: $1,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,837 · Education: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,836.94 |
| Education | $324.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $855.57 | 2021-2025 | |
| Lilly USA, LLC | $724.66 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $689.45 | 2022-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $531.41 | 2021-2025 | Dupixent |
| Janssen Biotech, INC. | $431.37 | 2021-2025 | Tremfya, Stelara, Remicade |
| Genzyme Corporation | $320.00 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $309.39 | 2021-2025 | |
| Dermavant Sciences, INC. | $294.66 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $288.41 | 2023-2025 | Sotyktu |
| Incyte Corporation | $201.86 | 2021-2025 | Opzelura |
| Pfizer INC. | $196.77 | 2023-2025 | |
| Leo Pharma INC. | $179.28 | 2022-2025 | Adbry |
| Organon LLC | $127.73 | 2025 | Vtama, Hadlima |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $46.53 | 2025 | Cabtreo, Jublia, Siliq |
| Amgen INC. | $38.72 | 2022-2023 | Otezla |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $16.95 | 2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.71 | 2022 | |
| Genentech USA, INC. | $16.19 | 2023 | Xolair |
| Galderma Laboratories, L.P. | $15.48 | 2024 | |
| Arcutis Biotherapeutics, INC. | $15.35 | 2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $13.97 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Engelbrecht listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.